ObsEva racks up $60 mln Series B

By Iris Dorbian — 3 months ago

Swiss biopharmaceutical company ObsEva, a developer of drugs that focus on “serious conditions compromising pregnancy from conception to birth,” has raised $60 million in Series B funding. The investors included HBM Healthcare Investments, New Enterprise Associates, OrbiMed, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, Novo Ventures and MS Ventures. In addition to the funding, Ed Mathers of NEA has been added to ObsEva’s board of directors. Leerink Partners LLC was the advisor on the funding.

Continue

First Aid Shot Therapy rakes in $24 mln Series C

By Iris Dorbian — 3 months ago

Burlingame, California-based First Aid Shot Therapy, a developer of over-the-counter medicine in liquid shot form, has raised $24 million in Series C funding. Johnson & Johnson Innovation – JJDC Inc led the round with participation from other investors that included Lumira Capital, Sofinnova Ventures, Redmile Group and HealthQuest Capital.

Continue

VC-backed Aclaris goes public

By Iris Dorbian — 4 months ago

Malvern, Pennsylvania-based Aclaris Therapeutics, a dermatology-focused specialty pharmaceutical company, has raised $55 million for its IPO after pricing its 5 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “ACRS.” Jefferies LLC and Citigroup Global Markets Inc are serving as the lead underwriters. Aclaris is backed by Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures

Continue

VC-backed Mirna Therapeutics debuts IPO

By Iris Dorbian — 5 months ago

Austin, Texas-based Mirna Therapeutics Inc, a biopharmaceutical company focused on developing cancer-treating drugs, has raised almost $44 million for its IPO after pricing its 6.25 million shares at $7 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “MIRN.” Citigroup and Leerink Partners are the lead underwriters. Mirna’s backers included Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners and Correlation Ventures.

Continue

James joins Thoma Bravo

By Luisa Beltran — 5 months ago

Jennifer James has joined Thoma Bravo LLC as Director, Head of Investor Relations & Marketing. James most recently served as Partner, Investor Relations & Marketing, for Sofinnova Ventures.

Continue

Checkmate Pharma raises $20 mln

By Luisa Beltran — 6 months ago

Checkmate Pharmaceuticals said Tuesday that it raised $20 million in Series A financing from Sofinnova Ventures and venBio. Checkmate is a biopharmaceutical company aimed at developing cancer immunotherapies.

Continue

Antiva Biosciences nabs $16 mln Series B

By Iris Dorbian — 6 months ago

Biopharmaceutical company Antiva Biosciences Inc has secured $16 million in Series B funding. Canaan Partners and Sofinnova Ventures led the round. In conjunction with the funding, Wende Hutton, a general partner at Canaan Partner and David Kabakoff, an executive partner at Sofinnova Ventures, have been added to Antiva’s board of directors. Also, the company has named Gail Maderis as president and CEO and Steven P. James as executive chairman of the board.

Continue

Aledia raises 28.4 mln euros in Series B funding

By Chris Witkowsky — 8 months ago

Aledia, which makes 3-D LEDs, has closed its Series B funding on about 28.4 million euros (about $31 million). Participants in the funding round include Valeo, an automobile-equipment maker, IKEA GreenTech, the venture arm of IKEA, and Ecotechnologies fund of Bpifrance, the French national industrial bank. Existing Aledia investors Sofinnova Partners, Braemar Energy Ventures, Demeter Partners and CEAi/ATi, also participated in the funding.

Continue

VC-backed aTyr Pharma rolls out IPO

By Iris Dorbian — 9 months ago

San Diego-based biotherapeutics company aTyr Pharma Inc has debuted its IPO after pricing its 5.36 million shares at $14 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets are serving as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

Continue

Edge Therapeutics racks up about $72.5 mln

By Iris Dorbian — 10 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

Continue

Natera reels in about $55.5 mln

By Iris Dorbian — 10 months ago

San Carlos, California-based Natera Inc, a provider of non-invasive genetic testing, has secured about $55.5 million in funding. Sofinnova Ventures led the round with participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors. In conjunction with the funding, Dr James Healy, a general partner at Sofinnova, has been appointed to Natera’s board of directors.

Continue

VC-backed aTyr files for IPO

By Iris Dorbian — 10 months ago

San Diego-based biotherapeutics company aTyr Pharma Inc has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading its stock on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc will serve as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

Continue

Atyr Pharma raises $76 mln

By Luisa Beltran — 11 months ago

Atyr Pharma Inc. said Tuesday it raised $76 million in Series E financing led by new investor Sofinnova Ventures and an undisclosed large institutional investor in the biotechnology industry. Also taking part in the round were T. Rowe Price Associates Inc.; Federated Investors Inc.; Deerfield; Rock Springs Capital Management; EcoR1 Capital; Sphera Global Healthcare and two additional undisclosed institutional investors. Atyr said current venture capital investors and a current public investment fund took part in the raise as well. San Diego-based Atyr Phrama is a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases.

Continue

Chiasma snags $70 mln Series E

By Iris Dorbian — 12 months ago

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.

Continue

VC-backed Ascendis Pharma goes public

By Iris Dorbian — 1 year ago

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.

Continue